| 摘要 |
This disclosure relates to a crystalline monohydrate of (4s)-4-(5-phenyl-1,3,4-thiadiazol-2-yloxy)-1-azatricyclo[3.3.1.13,7]decane dihydrogen citrate (Formula (I), which does not show the dihydrogen citrate) that crystallises when the mother liquor comprising a critical water activity of greater than or equal to 0.15. This compound modulates alpha7 nicotinic acetylcholine receptors and alpha4beta2 nicotinic acetylcholine receptors and may be used to treat conditions and disorders including neurodegenerative and cognitive disorders. Methods to crystallise the compound in this form are also disclosed, along with pharmaceutical compositions and methods for treating diseases by administering this compound. |
